Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences (formerly Suven Pharmaceuticals) has informed stock exchanges that the trading window for its securities will be closed for designated persons and their immediate relatives starting April 1, 2026. The closure will remain in effect until 48 hours after the company declares its audited financial results (standalone and consolidated) for the quarter and full year ending March 31, 2026. The date of the board meeting to approve these Q4 and FY26 results has not been announced yet and will be communicated later. This is a standard compliance filing under SEBI's Prohibition of Insider Trading Regulations, 2015.
This is a routine regulatory disclosure and not a material business event. It signals that the company is preparing to announce its full-year and March quarter earnings soon, which investors should watch for. The trading window restriction prevents insiders from trading shares before results are published, so retail investors are not directly affected.